Titan Biotech Limited Opens Special Window for Re-lodgement of Transfer Requests and Dematerialisation of Physical Shares

Titan Biotech Limited has notified shareholders and the general public about the opening of a Special Window for re-lodgement of transfer requests and dematerialisation of physical shares. The announcement was made via newspaper advertisements published on May 6, 2026, in Financial Express (English) and Naya India (Hindi), in compliance with SEBI Circular No. SEBI/HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026.

Special Window: Key Details

The Special Window has been opened to facilitate ease of investing for shareholders and to safeguard their rights in securities purchased by them. It is specifically available for the transfer and dematerialisation (demat) of physical securities which were sold or purchased prior to April 1, 2019. The following table summarises the key parameters of the Special Window:

Parameter:	Details
SEBI Circular Reference:	SEBI/HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026
Window Open Date:	February 5, 2026
Window Close Date:	February 4, 2027
Duration:	One year
Eligible Securities:	Physical securities sold/purchased prior to April 1, 2019
Earlier Deadline Missed:	January 6, 2026

Scope of the Special Window

In continuation of SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoB/P/CIR/2025/97 dated July 2, 2025, the Special Window is also available for transfer requests that were submitted earlier but were rejected, returned, or not attended to due to deficiencies in documents, process, or otherwise. Investors who were unable to meet the earlier deadline of January 6, 2026 may now avail of this opportunity.

How to Avail the Special Window

Eligible investors are required to furnish the requisite documents to the company's Registrar and Transfer Agent. The details are as follows:

Registrar and Transfer Agent: BEETAL Financial & Computer Services Pvt. Ltd.
Address: BEETAL HOUSE, 3rd Floor, 99 Madangir, Behind LSC, New Delhi - 110062
Tel.: 011-42959000, 011-29961281-283
Email: beetalrta@gmail.com

Regulatory Compliance and Disclosure

The communication was submitted to BSE Limited on May 6, 2026, and signed by Charanjit Singh, Company Secretary & Compliance Officer (M.No A12726), on behalf of Titan Biotech Limited. The advertisement and related disclosures are also available on the company's website at www.titanbiotechltd.com . The company's registered office and works are located at Unit I: A-902A, RIICO Industrial Area, Phase III, Bhiwadi-301019, Rajasthan, and Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.08%	-6.05%	-7.41%	+139.60%	+420.09%	+635.71%

Titan Biotech Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, to BSE Limited. The report was filed on May 4, 2026, by Compliance Officer Charanjit Singh, pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The secretarial audit was conducted by Practicing Company Secretary Mr. Amit Anand (M No: ACS-13409, CP No: 17101), with the report dated April 24, 2026, and issued from Delhi.

Scope of Examination

The secretarial audit covered an examination of all documents, records, filings, and submissions made by Titan Biotech to the stock exchanges, as well as the company's website and other relevant documents for the financial year ended March 31, 2026. The review assessed compliance with the following key regulatory frameworks:

SEBI Act, 1992 and regulations, circulars, and guidelines issued thereunder
Securities Contracts (Regulation) Act, 1956 (SCRA) and rules made thereunder
SEBI (LODR) Regulations, 2015
SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
SEBI (Prohibition of Insider Trading) Regulations, 2015

Certain regulations were noted as not applicable during the review period, including SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018; SEBI (Buyback of Securities) Regulations, 2018; SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; and SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021.

Compliance Status: No Deviations Recorded

The Practicing Company Secretary confirmed that Titan Biotech complied with all applicable SEBI regulations and circulars during the review period. No deviations, violations, fines, or regulatory actions were reported. The following table summarises the key compliance parameters reviewed:

Compliance Parameter:	Status	Remarks
Secretarial Standards (ICSI)	Yes	None
Adoption and updation of applicable policies	Yes	None
Maintenance and disclosures on website	Yes	None
Disqualification of Directors (Section 164, Companies Act, 2013)	Yes	Based on confirmation received from Directors
Identification of material subsidiaries	NA	No material subsidiary identified during review period
Disclosure requirements for subsidiaries	Yes	Policy for determining material subsidiary is in place
Preservation of documents	Yes	None
Performance evaluation of board and committees	Yes	None
Related party transactions – prior audit committee approval	Yes	None
Disclosure of events or information (Regulation 30)	Yes	None
Prohibition of Insider Trading (Regulation 3(5) & 3(6))	Yes	Company has proper Structural Digital Database software
Actions taken by SEBI or Stock Exchanges	Yes	None
Resignation of statutory auditors	NA	No resignation of statutory auditors during the review period
Additional non-compliances	Yes	No additional non-compliance observed

Actions on Previous Report Observations

The report also confirmed that there were no pending observations from previous secretarial compliance reports requiring remedial action. All entries under this section were marked as NA, indicating a clean compliance record carried forward from prior periods.

Assumptions and Limitations

The Practicing Company Secretary noted the following key limitations of the report:

Compliance with applicable laws and the authenticity of documents furnished are the responsibility of the management of the listed entity.
The report is based on examination of relevant documents and information and is neither an audit nor an expression of opinion.
The correctness and appropriateness of financial records and books of account were not verified.
The report is solely for the purpose of compliance under Regulation 24A(2) of the SEBI (LODR) Regulations, 2015, and does not constitute an assurance regarding the future viability of the entity or the efficacy of management conduct.

The report was signed by Amit Anand, Practicing Company Secretary, with UDIN: A013409H000196240 and Peer Review No.: 1970/2022, at Delhi on April 24, 2026.